Study of ensartinib for advanced ALK-positive lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This real-world study looks at how ensartinib works in people with advanced ALK-positive non-small cell lung cancer (NSCLC) whose disease has continued or worsened after ALK-targeted therapy. It may help doctors understand how well the treatment works and who benefits most in everyday care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage IIIb or stage IV NSCLC (confirmed by biopsy or cell test).
- Your tumor tests positive for ALK using one of these tests: FISH, IHC, RT-PCR, or NGS.
- Your cancer has progressed during or after prior ALK-TKI treatment.
- You feel able to do daily activities at level 0 to 2 (ECOG performance status) and are expected to live more than 3 months.
- You need (or can receive) radiotherapy, such as for bone, lung, or adrenal metastases.
- You can have required blood/urine lab testing and agree to effective birth control (or abstain) during the study and for 90 days after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the drug ensartinib can help prevent cancer from returning after standard chemoradiation in people with stage III ALK-mutated non-small cell lung cancer that cannot be removed by surgery. Enrolling those who have completed chemoradiation within the past 6 weeks without their cancer getting worse.
This study looks at how well the drug Ensartinib works when given before surgery to people with a certain type of lung cancer (ALK-positive NSCLC) that can be removed. The goal is to see if it helps shrink the tumor and is safe to take.
This trial tests the targeted therapy drug ensartinib given after surgery to prevent lung cancer from coming back. It is only for people whose tumor has an ALK gene change and who are in early to moderately advanced stages after complete removal.
This Phase 3 trial tests whether ensartinib given after surgery can lower the risk of lung cancer coming back in people with ALK-positive non-small cell lung cancer. You may be eligible if your tumor was completely removed and your recovery and lab tests meet specific requirements.
This trial tests an oral targeted therapy (Ensartinib) after surgery for patients with stage I ALK-positive lung cancer who have certain high-risk features. The goal is to see if it helps prevent cancer from returning.
This trial studies whether taking ensartinib (a targeted pill) after lung cancer surgery can lower the chance the cancer comes back. It is for people with ALK-positive non-small cell lung cancer (NSCLC) whose cancer has been fully removed and who have recovered from treatment.
Hear when a new Carcinoma, Non-Small-Cell Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.